LIFYORLI Launch Drives Oncology GrowthThe company raised its full-year 2026 revenue guidance to a range of $1.1 billion to $1.2 billion. The National Comprehensive Cancer Network listed the therapy as a preferred regimen 15 days after its approval, Corcept said. He said Corcept expects LIFYORLI’s U.S. annual revenue in platinum-resistant ovarian cancer alone to exceed $1 billion as adoption grows. Outside oncology, Corcept said its 175-patient Phase IIb MONARCH study of miricorilant in metabolic dysfunction-associated steatohepatitis, or MASH, has completed enrollment and is expected to produce data later this year. About Corcept Therapeutics (NASDAQ:CORT)Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders.